• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HER2 过表达在乳腺导管原位癌中的临床和生物学意义:来自单一机构的大型研究。

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.

机构信息

Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, Nottingham City Hospital, The University of Nottingham, Nottingham, UK.

Histopathology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt.

出版信息

Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8.

DOI:10.1038/s41416-019-0436-3
PMID:31065110
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6738110/
Abstract

BACKGROUND

Previous studies have reported up to 50% of ductal carcinoma in situ (DCIS), is HER2 positive, but the frequency of HER2-positive invasive breast cancer (IBC) is lower. The aim of this study is to characterise HER2 status in DCIS and assess its prognostic value.

METHODS

HER2 status was evaluated in a large series of DCIS (n = 868), including pure DCIS and DCIS associated with IBC, prepared as tissue microarrays (TMAs). HER2 status was assessed using immunohistochemistry (IHC) and chromogenic in situ hybridisation (CISH).

RESULTS

In pure DCIS, HER2 protein was over-expressed in 9% of DCIS (3+), whereas 15% were HER2 equivocal (2+). Using CISH, the final HER2 status was positive in 20%. In mixed DCIS, HER2 amplification of the DCIS component was detected in 15% with amplification in the invasive component of only 12%. HER2-positive DCIS was associated with features of aggressiveness (p < 0.0001) and more frequent local recurrence (p = 0.03). On multivariate analysis, combined HER2+/Ki67+ profile was an independent predictor of local recurrence (p = 0.006).

CONCLUSIONS

The frequency of HER2 positivity in DCIS is comparable to IBC- and HER2-positive DCIS is associated with features of poor prognosis. The majority of HER2 over-expression in DCIS is driven by gene amplification.

摘要

背景

先前的研究报告称,多达 50%的导管原位癌(DCIS)为 HER2 阳性,但 HER2 阳性浸润性乳腺癌(IBC)的频率较低。本研究旨在描述 DCIS 中的 HER2 状态,并评估其预后价值。

方法

使用组织微阵列(TMA)评估了大量 DCIS(n=868)中的 HER2 状态,包括纯 DCIS 和与 IBC 相关的 DCIS。使用免疫组织化学(IHC)和显色原位杂交(CISH)评估 HER2 状态。

结果

在纯 DCIS 中,9%的 DCIS(3+)HER2 蛋白过表达,而 15%的 HER2 状态不确定(2+)。使用 CISH,最终 HER2 状态阳性率为 20%。在混合 DCIS 中,仅检测到 DCIS 成分的 HER2 扩增,其阳性率为 15%,而浸润性成分的 HER2 扩增率为 12%。HER2 阳性的 DCIS 与侵袭性特征(p<0.0001)和更高的局部复发率(p=0.03)相关。多变量分析显示,HER2+/Ki67+联合表型是局部复发的独立预测因子(p=0.006)。

结论

DCIS 中 HER2 阳性的频率与 IBC 相似,并且 HER2 阳性的 DCIS 与不良预后特征相关。DCIS 中 HER2 过表达的大多数是由基因扩增驱动的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/6738110/214916a39e8e/41416_2019_436_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/6738110/846074d22a24/41416_2019_436_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/6738110/214916a39e8e/41416_2019_436_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/6738110/846074d22a24/41416_2019_436_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405b/6738110/214916a39e8e/41416_2019_436_Fig2_HTML.jpg

相似文献

1
The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.HER2 过表达在乳腺导管原位癌中的临床和生物学意义:来自单一机构的大型研究。
Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8.
2
Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.根据 HER2 扩增状态和分子亚型对乳腺导管原位癌 (DCIS) 的组织病理学特征进行描述。
Virchows Arch. 2014 Sep;465(3):275-89. doi: 10.1007/s00428-014-1609-3. Epub 2014 Jun 29.
3
HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.通过荧光原位杂交和免疫组织化学检测纯导管原位癌以及浸润性导管癌的导管内和浸润成分中的HER2状态。
Histopathology. 2006 May;48(6):702-7. doi: 10.1111/j.1365-2559.2006.02403.x.
4
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.人表皮生长因子受体2(HER2)表达在导管原位癌(DCIS)中的预后作用:一项基于人群的队列研究。
BMC Cancer. 2015 Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.
5
Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.乳腺癌亚组间HER2扩增状态的比较为乳腺癌进展途径提供了新见解。
Virchows Arch. 2017 Nov;471(5):575-587. doi: 10.1007/s00428-017-2161-8. Epub 2017 May 31.
6
Molecular phenotypes of DCIS predict overall and invasive recurrence.DCIS 的分子表型可预测总体和浸润性复发。
Ann Oncol. 2015 May;26(5):1019-1025. doi: 10.1093/annonc/mdv062. Epub 2015 Feb 12.
7
Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.系统评估乳腺导管原位癌的 HER2 状态:潜在临床相关性的视角。
Breast Cancer Res. 2024 Aug 27;26(1):125. doi: 10.1186/s13058-024-01875-w.
8
Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.伴有微浸润的乳腺导管原位癌的生物学行为及长期预后
Oncotarget. 2016 Sep 27;7(39):64182-64190. doi: 10.18632/oncotarget.11639.
9
Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.HER2/Neu在乳腺导管原位癌及非典型导管增生性病变中的可能预后作用
Asian Pac J Cancer Prev. 2016;17(8):3733-6.
10
Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.原发性导管原位癌(DCIS)与相应局部病变之间乳腺癌受体的克隆性改变。
Eur J Cancer. 2014 Feb;50(3):517-24. doi: 10.1016/j.ejca.2013.10.020. Epub 2013 Nov 22.

引用本文的文献

1
Development and Validation of a Predictive Model for Sentinel Lymph Node Biopsy Exemption in Ductal Carcinoma in situ Patients.导管原位癌患者前哨淋巴结活检豁免预测模型的开发与验证
Breast Care (Basel). 2025 Jun 12. doi: 10.1159/000546885.
2
Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS.浸润性导管癌及并存的导管原位癌中HER2表达的定量评估。
Breast Cancer Res Treat. 2025 Jul 18. doi: 10.1007/s10549-025-07781-9.
3
Is the risk of local recurrence higher for microinvasive breast cancer vs. early stage invasive breast cancer?

本文引用的文献

1
Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.硫氧还蛋白相互作用蛋白是乳腺导管原位癌的独立危险分层因子。
Mod Pathol. 2018 Dec;31(12):1807-1815. doi: 10.1038/s41379-018-0086-7. Epub 2018 Jun 28.
2
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.临床相关性和 HER2 状态在局部和中心检测中的一致性——12 年间 1581 例 HER2 阳性乳腺癌的分析。
Mod Pathol. 2018 Apr;31(4):607-615. doi: 10.1038/modpathol.2017.171. Epub 2017 Dec 22.
3
Prediction of heterogeneity in breast cancer immunophenotype at ductal carcinoma stage?
与早期浸润性乳腺癌相比,微浸润性乳腺癌的局部复发风险更高吗?
Breast Cancer Res Treat. 2025 Jun;211(2):479-487. doi: 10.1007/s10549-025-07664-z. Epub 2025 Mar 3.
4
Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.系统评估乳腺导管原位癌的 HER2 状态:潜在临床相关性的视角。
Breast Cancer Res. 2024 Aug 27;26(1):125. doi: 10.1186/s13058-024-01875-w.
5
Accurate and efficient integrative reference-informed spatial domain detection for spatial transcriptomics.准确且高效的整合参考信息的空间转录组学空间域检测。
Nat Methods. 2024 Jul;21(7):1231-1244. doi: 10.1038/s41592-024-02284-9. Epub 2024 Jun 6.
6
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.从导管原位癌到浸润性乳腺癌的进展:分子特征及临床意义。
Signal Transduct Target Ther. 2024 Apr 3;9(1):83. doi: 10.1038/s41392-024-01779-3.
7
formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer.该公式增强了曲妥珠单抗对 HER2 阳性乳腺癌的抑制作用。
Acta Biochim Biophys Sin (Shanghai). 2024 Mar 25;56(3):462-473. doi: 10.3724/abbs.2023281.
8
Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.高级别乳腺导管原位癌(DCIS)的亚型:发生率和潜在的临床影响。
Breast Cancer Res Treat. 2023 Sep;201(2):329-338. doi: 10.1007/s10549-023-07016-9. Epub 2023 Jul 15.
9
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ.Ⅱ期临床试验:Nelipepimut-S 肽疫苗用于乳腺导管原位癌女性患者
Cancer Prev Res (Phila). 2023 Jun 1;16(6):333-341. doi: 10.1158/1940-6207.CAPR-22-0388.
10
HER2 Overexpression and Cytogenetical Patterns in Canine Mammary Carcinomas.犬乳腺癌中HER2过表达与细胞遗传学模式
Vet Sci. 2022 Oct 22;9(11):583. doi: 10.3390/vetsci9110583.
导管癌阶段乳腺癌免疫表型异质性的预测?
J Cancer Res Ther. 2016 Oct-Dec;12(4):1249-1256. doi: 10.4103/0973-1482.199541.
4
Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology.利用组织芯片技术评估新型蛋白质在乳腺癌中的意义
Methods Mol Biol. 2017;1501:311-325. doi: 10.1007/978-1-4939-6475-8_16.
5
Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery.保乳手术后导管原位癌复发的预测因素
J Breast Cancer. 2016 Jun;19(2):185-90. doi: 10.4048/jbc.2016.19.2.185. Epub 2016 Jun 24.
6
Detection of Gene Amplification by Multiplex Ligation-Dependent Probe Amplification in Comparison with In Situ Hybridization and Immunohistochemistry.多重连接依赖探针扩增法检测基因扩增并与原位杂交和免疫组织化学法作比较
Asian Pac J Cancer Prev. 2015;16(17):7997-8002. doi: 10.7314/apjcp.2015.16.17.7997.
7
Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.导管原位癌诊断后的乳腺癌死亡率。
JAMA Oncol. 2015 Oct;1(7):888-96. doi: 10.1001/jamaoncol.2015.2510.
8
A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.一项基于人群的验证性研究,评估DCIS评分对仅接受保乳手术治疗的个体复发风险的预测作用。
Breast Cancer Res Treat. 2015 Jul;152(2):389-98. doi: 10.1007/s10549-015-3464-6. Epub 2015 Jun 29.
9
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.人表皮生长因子受体2(HER2)表达在导管原位癌(DCIS)中的预后作用:一项基于人群的队列研究。
BMC Cancer. 2015 Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.
10
Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis.乳腺导管原位癌局部浸润性复发的预测因素:一项荟萃分析。
Eur J Cancer Prev. 2016 Jan;25(1):19-28. doi: 10.1097/CEJ.0000000000000131.